Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xi Yan

Showing results (661-670 of 662) with videos related to

Pageof 67
Sort By:
You have reached the last page of results.This site can display upto 662 results.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Gut|May 27, 2018
Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trialQian Chen, Chang Shu, Arian D Laurence, et al.
Pageof 67

Showing results (661-670 of 662) with videos related to

Sort By:
Pageof 67
You have reached the last page of results.This site can display upto 662 results.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Gut|May 27, 2018
Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trialQian Chen, Chang Shu, Arian D Laurence, et al.
Pageof 67